Work

Nautilus, a phase 1b/2 trial of combining oral HDAC inhibitor (HDACi) with MEK inhibitor (MEKi) in patients with NRAS-mutated metastatic melanoma (MM).

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.9552

Authors: Rodabe Navroze Amaria, Herbert Leon Duvivier, Katy K. Tsai, Parisa Momtaz, Robert W. Galamaga, Evan P. Pisick, Bently Patrick Doonan, Amy M. Weise, Natalie Langr, James D. Winkler, Harish P. Dave, Jennifer Robinson Diamond, Ryan J. Sullivan

Institutions: The University of Texas MD Anderson Cancer Center, City of Hope, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, University of Florida Health, University of Florida, Henry Ford Hospital, University of Colorado Anschutz, Massachusetts General Hospital

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410816757

Cites:

Cited by: 1

Related to: 10